Lunai Bioworks Inc. 8-K

What Happened

• Lunai Bioworks (LNAI) filed an 8‑K reporting two material actions: (1) agreements to exchange $828,770.14 of secured promissory notes for common stock and warrants, and (2) a binding March 26, 2026 Acquisition Agreement with Clemann Group for blood-brain barrier delivery technology and Alzheimer’s CNS drug assets structured as a $20.0 million strategic investment.
• The $20.0M investment will be issued as Series B Convertible Preferred Stock with a fixed conversion price of $1.50 per share and a 19.9% beneficial ownership limitation; the Preferred Stock contains no variable pricing or reset provisions. The Acquisition Agreement contains customary closing conditions and may not be completed.

Key Details

• Debt exchange: Holders agreed to cancel $828,770.14 of principal and accrued interest in exchange for 3,909,293 common shares (implied $0.21/share) plus common stock purchase warrants for 1,433,621 additional shares.
• Warrants: Each warrant will be immediately exercisable for one share at $0.21 per share and expire March 24, 2036.
• Conditions/approvals: Issuance of Exchange Shares and shares from warrant exercise requires the Company to submit a Nasdaq Additional Shares Notification Form and clear any Nasdaq comments, obtain board approval and satisfy customary closing conditions; the board approved the debt exchange on March 23, 2026. Press release issued March 26, 2026.
• Security release: At closing the Investor Notes will be canceled and related security interests under the Amended and Restated Security Agreement (dated Jan 2, 2024) will be released.

Why It Matters

• The debt-for-equity exchange reduces Lunai’s secured debt by ~$828.8K and replaces that liability with equity and long‑dated warrants, which lowers near-term cash obligations but increases potential share count (dilution).
• The $20M Preferred Stock investment brings significant committed capital and transfers ownership of a blood‑brain‑barrier delivery platform and CNS Alzheimer’s assets to Lunai, which could materially affect the company’s pipeline and strategy if the transaction closes.
• Important investor considerations: conversion terms (fixed $1.50 conversion price) and a 19.9% ownership cap limit how much a single holder can convert; issuance of shares is subject to Nasdaq clearance and other closing conditions, so timing and completion are not guaranteed.